6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells

Area of Science:

• Biochemistry
• Cancer Biology
• Metabolic Regulation

Background:

• The enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4) is a key regulator of glycolysis.
• The tumor suppressor protein p53 plays a critical role in cellular homeostasis and cancer prevention.
• p53-deficient cancers exhibit altered metabolic dependencies.

Purpose of the Study:

• To investigate the regulatory relationship between p53 and PFKFB4.
• To determine the functional role of PFKFB4 in p53-deficient cancer cells.
• To explore PFKFB4 as a potential therapeutic target in cancer.

Main Methods:

• Analysis of PFKFB4 gene expression regulation by p53.
• Depletion of PFKFB4 in p53-deficient cancer cells.
• Measurement of glycolytic flux, pentose-phosphate pathway activity, and NADPH levels.
• Assessment of cellular biosynthesis, reactive oxygen species, and apoptosis.
• In vivo tumor growth inhibition studies.

Main Results:

• p53 downregulates PFKFB4 expression via promoter binding and histone deacetylase activity.
• PFKFB4 depletion in p53-deficient cells increases fructose-2,6-bisphosphate and glycolysis.
• PFKFB4 is crucial for NADPH synthesis and regeneration in p53-deficient cells.
• PFKFB4 deficiency leads to reduced biosynthesis, increased reactive oxygen species, and cell death.
• Silencing PFKFB4 inhibits tumor growth and induces apoptosis in p53-deficient cancers.

Conclusions:

• PFKFB4 is essential for anabolic metabolism and survival of p53-deficient cancer cells.
• Targeting PFKFB4 represents a promising therapeutic strategy for cancers lacking p53 function.
• The p53-PFKFB4 axis offers insights into cancer metabolic vulnerabilities.